Thrombocytopenia Induced in Mice by Thromboplastin Infusion – Essential Role of the Third Complement Component

Luis A Giraudo; Agustin P Dalmasso

doi:10.1055/s-0038-1646750

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1978; 39(03): 733-742
DOI: 10.1055/s-0038-1646750

Original Article

Schattauer GmbH Stuttgart

Thrombocytopenia Induced in Mice by Thromboplastin Infusion – Essential Role of the Third Complement Component

Authors

Luis A Giraudo

The University of Minnesota Medical School, Department of Laboratory Medicine and Pathology, Veterans Administration Hospital, Minneapolis, Minnesota 55417, U.S.A.
Agustin P Dalmasso

The University of Minnesota Medical School, Department of Laboratory Medicine and Pathology, Veterans Administration Hospital, Minneapolis, Minnesota 55417, U.S.A.

Abstract

PDF Download

Summary

Studies were performed in mice to investigate the effects of the slow infusion of brain thromboplastin (tissue factor) on blood platelet levels. Thromboplastin caused pronounced thrombocytopenia in all strains of mice tested without histological evidence of intravascular coagulation. The role of the complement system in the thrombocytopenic response to thromboplastin administration was evaluated by using complement-deficient animals. Depending on experimental conditions, the degree of platelet reduction in C5-deficient mice was similar to or significantly lower than in normocomplementemic animals. C5-deficient mice reconstituted with mouse plasma or purified human C5 had a thrombocytopenic reaction identical to that of normocomplementemic controls. The thrombocytopenic response of B10.D2/new and old line mice could be abrogated by inactivating C3 with cobra venom factor prior to the administration of thromboplastin. We conclude that in mice C3 plays a central role in the thrombocytopenia induced by thromboplastin infusion, while C5 (and/or other late acting components) plays only a minor role. In vivo activation of complement by thromboplastin was indicated by the finding that thromboplastin infusion in B10.D2/new mice caused a significant reduction in total serum hemolytic complement and a slight reduction in C3 measured immunochemically. The platelet counts of uninjected B10.D2/new mice were slightly but significantly higher than in B10.D2/old mice.

PDF (1021 kb)

References

References
1 Albrechtsen OK, Brakman P, Astrup T. 1970; The defibrination syndrome in rabbits following infusion of tissue thromboplastin in the jugular vein. Thrombosis et Diathesis Haemorrhagica 24: 113
2 Ballow M, Cochrane CG. 1969; Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them. Journal of Immunology 103: 944
3 Boyer JT, Gall EP, Norman ME, Nilsson UR, Zimmerman TS. 1975; Hereditary deficiency of the seventh component of complement. Journal of Clinical Investigation 56: 905
4 Branson HE, Wyatt LL, Schmer G. 1976; Complement consumption in acute disseminated intravascular coagulation without antecedent immunopathology. American Journal of Clinical Pathology 66: 967
5 Brecher G, Cronkite EP. 1950; Morphology and enumeration of human blood platelets. Journal of Applied Physiology 3: 365
6 Breckenridge RT, Rosenfeld SI, Graff KS, Leddy JP. 1977; Hereditary C5 deficiency in man. III. Studies of hemostasis and platelet responses to zymosan. Journal of Immunology 118: 12
7 Brown DL. 1975; Complement and coagulation. British Journal of Haematology 30: 377
8 Cinader B, Dubiski S, Wardlaw AC. 1964; Distribution, inheritance, and properties of an antigen, MuBl, and its relation to hemolytic complement. Journal of Experimental Medicine 120: 897
9 Cochrane CG, Müller-Eberhard HJ, Aikin BS. 1970; Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. Journal of Immunology 105: 55
10 Dalmasso AP, Lee M, Giraudo L, Swaim WR. 1973; Participation of complement in an experimental model of intravascular coagulation. Journal of Immunology 111: 298
11 Gomberts ED, Rabson AR. 1977; Coagulation studies in a patient with homozygous C3 deficiency. British Journal of Haematology 35: 165
12 Grossklaus C, Damerau B, Lemgo E, Vogt W. 1976; Induction of platelet aggregation by the complement-derived peptides C3a and C5a. Naunyn-Schmiedeberg–s Archives of Pharmacology 295: 71
13 Henson PM. 1969; The adherence of leukocytes and platelets induced by fixed IgG antibody or complement. Immunology 16: 107
14 Heusinkveld RS, Leddy JP, Klemperer MR, Breckenridge RT. 1974; Hereditary deficiency of the sixth component of complement in man. II. Studies of hemostasis. Journal of Clinical Investigation 53: 554
15 Jarvinen JA, Dalmasso AP. 1977; Trypanosoma musculi infections in normocomplementemic, C5-deficient and C3-depleted mice. Infection and Immunity 16: 557
16 Kalowski S, Howes Jr EL, Margaretten W, Mckay DG. 1975; Effects of intravascular clotting on the activation of the complement system: the role of the platelet. American Journal of Pathology 78: 525
17 Lee ML, Lee MY, Dalmasso AP, Swaim WR. 1974; Abnormal platelet response to thromboplastin infusion in rabbits deficient in the sixth component of complement. Proceedings of the Society for Experimental Biology and Medicine 146: 732
18 Mardiney MR, Müller-Eberhard HJ. 1965; Mouse βlc-globulin: production of antiserum and characterization in the complement reaction. Journal of Immunology 94: 877
19 Monkhouse FC, Milojevic S. 1960; Changes in fibrinogen level after infusion of thrombin and thromboplastin. American Journal of Physiology 199: 1165
20 Nilsson UR, Müller-Eberhard HJ. 1967; Deficiency of the fifth component of complement in mice with an inherited complement defect. Journal of Experimental Medicine 125: 1
21 Nilsson UR, Tomar RH, Taylor Jr FB. 1972; Additional studies on human C5 : Development of a modified purification method and characterization of the purified product by polyacrylamide gel electrophoresis. Immunochemistry 9: 709
22 Owen Jr CA, Bowie EJW, Thompson Jr JH. 1975. Thediagnosisofbleedingdisorders. 2nd edn Little, Brown, and Co; Boston: 112
23 Pfueller SL, LüScher EF. 1974; Studies of the mechanisms of the human platelet release reaction induced by immunologic stimuli. II. The effects of zymosan. Journal of Immunology 112: 1211
24 Pitlick FA, Nemerson Y. 1970; Binding of the protein component of tissue factor to phospholipids. Biochemistry 9: 5105
25 Quick AJ. 1957. Hemorrhagic Diseases. Lea & Febiger; Philadelphia: 380
26 Ratnoff OD. 1969; Some relationships among hemostasis, fibrinolytic phenomena, immunity, and the inflammatory response. Advances in Immunology 10: 145
27 Simmons WH, Burkholder DE, Brecher AS. 1976; The hydrolysis of biologically active peptides by bovine lung tissue factor (thromboplastin). Proceedings of the Society for Experimental Biology and Medicine 152: 576
28 Siraganian RP. 1972; Platelet requirement in the interaction of the complement and clotting systems. Nature (New Biology) 239: 208
29 Sullivan Jr JD, Watson SW. 1974; Factors affecting the sensitivity of Limulus lysate. Applied Microbiology 28: 1023
30 Terry WD, Borsos T, Rapp HJ. 1964; Differences in serum complement activity among inbred strains of mice. Journal of Immunology 92: 576
31 Tomar RH, Kolchins D. 1972; Complement and coagulation. Serum βlc–βla in disseminated intravascular coagulation. Thrombosis et Diathesis Haemorrhagica 27: 389
32 Zeldis SM, Nemerson Y, Pitlick FA, Lentz TL. 1972; Tissue factor (thromboplastin): localization to plasma membranes by peroxidase-conjugated antibodies. Science 175: 766
33 Zimmerman TS, Arroyave CM, Müller-Eberhard HJ. 1971; A blood coagulation abnormality in rabbits deficient in the sixth component of complement (C6) and its correction by purified C6. Journal of Experimental Medicine 134: 1591
34 Zucker MB, Grant RA, Alper CA, Goodkofsky I, Lepow IH. 1974; Requirement for complement components and fibrinogen in the zymosan-induced release reaction of human blood platelets. Journal of Immunology 113: 1744